FDA Misses Hemp Guidance Deadline as Federal Ban Nears

Hemp companies bracing for a federal crackdown on intoxicating cannabinoid products this fall are still waiting on guidance that the government was legally required to deliver months ago. The Food and Drug Administration has blown past a deadline to publish the cannabinoid lists and packaging definitions that will decide which hemp products survive once a sweeping new federal standard takes effect on November 12, 2026, and congressional researchers are now flagging the delay.

What the FDA was supposed to deliver

When President Donald Trump signed a year-end spending package in November 2025, it carried a provision that quietly rewrote federal hemp law. The 2018 Farm Bill legalized hemp and its derivatives as long as they contained no more than 0.3 percent delta-9 THC by dry weight, a threshold that let a multibillion-dollar market in delta-8, THCA, and other intoxicating cannabinoids flourish. The new law scraps that delta-9 yardstick for a total-THC standard and caps finished hemp products at 0.4 milligrams of total THC per container, a level low enough to push most edibles, drinks, and tinctures off legal shelves once it takes hold.

To help the industry and law enforcement see exactly where the new lines fall, the law gave the FDA 90 days, until February 10, 2026, to publish three reference lists: every cannabinoid the agency knows can occur naturally in a cannabis plant, every naturally occurring THC-class cannabinoid, and every other compound with effects similar to THC or marketed that way. The agency was also told to spell out what counts as a container, the unit that the 0.4-milligram cap is measured against. The statute already describes a container as the innermost packaging touching a finished product, a jar, bottle, bag, can, or cartridge, but leaves the finer points to the FDA.

None of it has appeared. The Congressional Research Service, the nonpartisan analytical arm that advises lawmakers, noted in a report published late last month that the required guidance, due within 90 days of enactment, had not been published as of May 2026.

Why the delay matters for operators

The lists are not an academic exercise. The narrowed definition turns on whether a given cannabinoid can be naturally produced by the cannabis plant; products built on compounds that cannot, or that are synthesized outside the plant, are cut out of the hemp category and revert to marijuana under federal drug law. Without the agency’s catalog, producers, retailers, and police are left guessing which compounds fall on which side of that line. The same fog surrounds the container question. A per-container cap means little until everyone agrees on what a container is, and formats from multipacks to multi-serving bottles hang in the balance.

The timing is the problem. Once the change takes effect, products that fall outside the tighter definition stop being hemp and become marijuana, a Schedule I controlled substance, regardless of how a state regulates them. The federal redefinition applies uniformly in every state, whether a state’s own hemp rules run stricter or looser. Companies have spent the one-year runway since enactment trying to reformulate, relabel, or exit the category, but they cannot finish that work without knowing how the agency will read the statute. Lawmakers from both parties have filed bills and amendments to delay or undo the change, including a recent Republican-led push, though none have reshaped the law.

What Congress and the White House want

The Congressional Research Service framed the missing guidance as one of several implementation questions Congress may want to examine, suggesting lawmakers could review how the U.S. Department of Agriculture rewrites its domestic hemp program and how the new definition affects farmers, law enforcement, and consumers. The Department of Health and Human Services, the FDA’s parent agency, signaled earlier in 2026 that it still intended to publish the lists on time through the Federal Register, but nothing has materialized, and officials have not offered a new timeline.

The delay also lands in the middle of an unresolved fight over the law itself. A House committee recently blocked a set of hemp amendments from reaching the floor, leaving the November change on track. The Trump administration, for its part, has tried to thread the needle: the White House said this month that it wants Congress to amend the law so full-spectrum CBD products stay legal while genuinely intoxicating products are restricted, echoing a call the president made in April 2026. That approach assumes Congress acts in time, and it leaves untouched the guidance the FDA was already required to produce in February.

For hemp businesses, that leaves an uncomfortable gap. The instructions meant to tell them which products they can keep selling are months overdue, and the law behind them could still change before it ever takes effect. With the FDA silent, the more consequential signal may come from Congress.